This further suggests that, in addition to significantly reducing tumor burden and prolonging survival, TGFβ-blocking HSC gene therapy in combination with IR provided a long-term protection against cancer through the development of memory T cell responses in 1⁄4 of the mice. This evidence concerns the gene TGFB1 and neoplasm.